Synthetic antigens representing the antigenic variation of human hepatitis C virus

Viral Immunology

Volumn 23, Issue 5, 2010, Pages 497-508

  Kang, Kyung Hee ^a   Yamamura, Yasuhiro ^d   Carlos, Maria P ^a   Karvelas, Nicolas ^a   Kim, In Sup ^a   Sunkara, Deepa ^a   Rivera, Rebecca ^a   Gardner, Murray B ^a   Anderson, David E ^b   Diaz Mitoma, Francisco ^c   Torres, José V ^a   Marquez, Juan P ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^e Sonora Cancer Research Center   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; SYNTHETIC PEPTIDE; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGENIC VARIATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; GENOTYPE; HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INBRED STRAIN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTBRED STRAIN; PLASMA; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; ANTIGENS, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

HEPATITIS C VIRUS; MUS;

EID: 77957732562     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0043     Document Type: Article

References (41)

1. Aberle JH, Formann E, Steindl-Munda P, et al.: Prospective study of viral clearance and CD4 (+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006;36:24-31.
2. Anderson DE, Malley A, Benjamini E, Gardner MB, and Torres JV: Hypervariable epitope constructs as a means of accounting for epitope variability. Vaccine 1994;12:736-740.
3. Anderson DE, Singapuri A, Kang KH, Montefiori DC, and Torres JV: Timing of retroviral infection influences anamnestic immune response in vaccinated primates. Viral Immunol 2005;18:689-694.
4. Blum HE: Variants of hepatitis B, C and D viruses: molecular biology and clinical significance. Digestion 1995;56:85-95.
5. Bowen DG, and Walker CM: Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-952.
6. Brunetto MR, Suzuki T, Aizaky H, et al.: Variations in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear associated with virus persistence independently of liver disease. Ital J Gastroenterol 1996;28:499-504.
7. Caetano J, Martinho A, Paiva A, Pais B, Valente C, and Luxo C: Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J Virol 2008;82:7567-7577.
8. Carlos MP, Anderson DE, Gardner MB, and Torres JV: Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein. AIDS Res Hum Retroviruses 2000;16:153-161.
9. Carlos MP, Yamamura Y, Vu Q, Conzen K, Anderson DE, and Torres JV: Humoral immunity to immunodominant epitopes of hepatitis C virus in individuals infected with genotypes 1a or 1b. Clin Immunol 2004;111:22-27.
10. Chang JC, Seidel C, Ofenloch B, Jue DL, Fields HA, and Khudyakov YE: Antigenic heterogeneity of the hepatitis C virus NS4 protein as modeled with synthetic peptides. Virology 1999;257:177-190.
11. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, and Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
12. Chu CM, Sheen IS, and Liaw YF: Low-level hepatitis C viremia and humoral immune response to NS4 in chronic hepatitis B virus-hepatitis C virus coinfection. Scand J Gastroenterol 2004;39:778-782.
13. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, and Naoumov NV: Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000;118:346-355.
14. Diepolder HM, Gerlach JT, Zachoval R, et al.: Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997;71:6011-6019.
15. Gerlach JT, Ulsenheimer A, Gruner NH, et al.: Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol 2005;79:12425-12433.
16. Grakoui A, Shoukry NH, Woollard DJ, et al.: HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.
17. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, and Shimotohno K: Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991;175:220-228.
18. Hong Z, Ferrari E, Wright-Minogue J, et al.: Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol 1996;70:4261-4268.
19. Krishnadas DK, Li W, Kumar R, Tyrrell LJ, and Agrawal B: In vitro activation and differentiation of naive CD4+ and CD8+ T cells into HCV core-and NS3-specific armed effector cells: a new role for CD4+ T cells. Cell Immunol 2009;259:141-149.
20. Law M, Maruyama T, Lewis J, et al.: Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25-27.
21. Li K, Foy E, Ferreon JC, Nakamura M, et al.: Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005;102:2992-2997.
22. Meyer D, Anderson DE, Gardner MB, and Torres JV: Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques. AIDS Res Hum Retroviruses 1998;14:751-760.
23. Meyer D, and Torres JV: Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs. Viral Immunol 1999;12:117-129.
24. Nguyen MH, and Keeffe EB: Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9. Rev Gastroenterol Disord 2004;4(Suppl 1): S14-S21.
25. Pestka JM, Zeisel MB, Blaser E, et al.: Rapid induction of virus-neutralizing antibodies and viral clearance in a singlesource outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025-6030.
26. Purcell R: The hepatitis C virus: overview. Hepatology 1997;26:11S-14S.
27. Rispeter K, Lu M, Behrens SE, Fumiko C, Yoshida T, and Roggendorf M: Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection. Virus Genes 2000;21:179-188.
28. Sarobe P, Lasarte JJ, Garcia N, Civeira MP, Borras-Cuesta F, and Prieto J: Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. J Viral Hepat 2006;13:47-55.
29. Schulze zur Wiesch J, Lauer GM, Day CL, et al.: Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005;175:3603-3613.
30. Semmo N, and Klenerman P: CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol 2007;13:4831-4838.
31. Shoji I, Suzuki T, Chieda S, et al.: Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli. Hepatology 1995;22:1648-1655.
32. Simmonds P: Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004;85:3173-3188.
33. Smyk-Pearson S, Tester IA, Klarquist J, Palmer BE, Pawlotsky M, Golden-Mason L, and Rosen HR: Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol 2008;82:1827-1837.
34. Troesch M, Meunier I, Lapierre P, Lapointe N, Alvarez F, Boucher M, and Soudeyns H: Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 2006;352:357-367.
35. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, and McKeating JA: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007;132:667-678.
36. Wang H, and Eckels DD: Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. J Immunol 1999;162:4177-4183.
37. Wei L, Wang Y, Du S, Wang H, and Tao Q: Genetic variability and characterization of non-structural region 5 of hepatitis C virus genome from Chinese patients. J Gastroenterol 1998;33:62-72.
38. Weiner AJ, Brauer MJ, Rosenblatt J, et al.: Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991;180:842-848.
39. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, and Rosen HR: Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003;37:577-589.
40. Yerly D, Heckerman D, Allen TM, et al.: Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol 2008;82:3147-3153.
41. Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, and Baumert TF: Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 2007;13:4824-4830.